TRIPASS XR تري باس

 

for giardiasis, 1704t

for hookworm, 1704t

for pinworm, 1708

Mechlorethamine, 469t, 1979t, 1981t

for HL, 2041

Meclizine (Bonine), 468t, 975, 976t

Meclofenamate, 870t

Medroxyprogesterone (Progestins)

for endometriosis, 1021–1022

for polycystic ovary syndrome, 1012t

Medroxyprogesterone acetate, 947–948, 1033t

Mefloquine, 49, 1696, 1698t, 1701

for depressive disorders, 1815t

Mefoxin (see Cefoxitin)

Megestrol, 88

Melatonin, 1768, 1776

for sleep, 1861

Meloxicam, 870t, 887, 888t

Melphalan, 469t, 470t, 1979t, 1987, 1991t, 1995t, 2004, 2037t

for blood progenitor cell rescue, 2005

Memantine, 88

for Alzheimer’s disease, 2239

MEN 1 (see Multiple endocrine neoplasia type 1)

Menactra, 1359

Menest (see Esterified estrogen)

Meningitis, for sepsis, 2186t

Meningococcal conjugate vaccine (MCV4), 1368

Menthol, 1626

Menveo, 1359

Meperidine, 677, 677t (see also Opioids)

dosage of, 1199t

Mepivacaine, 1177t

Meradimate, 849t

Mercaptobenzothiazole, 822t

Mercaptopurine, 470t, 918t, 1996, 1996t, 2017

for ALL, 2017t

dosage, 2017–2018

for T-cell lymphomas, 2020t

Merem (see Meropenem)

Meropenem (Merem), 1326t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

for cystic fibrosis, 461t

dosing of, 1337t

for febrile neutropenia, 1562

for gram-negative bacillary meningitis, 1378

for meningitis, 1378

for skin and soft tissue infections, 1550

for UTI, 1497t

Mesalamine (Apriso; Asacol HD; Delzicol; Lialda; Pentasa), 520, 521t, 523, 523t

Mesalamine enema (Rowasa), 523t

Mesalamine suppository (Canasa), 523t

Mescaline, 1885

Mesna, 709, 1992–1993

Metaxalone, 1186t

Metformin, 644, 678, 980, 1137t (see also Biguanide)

adverse effects of, 1112

clinical use of, 1113

contraindications and precautions of, 1112–1113

for diabetes, 167

doses of, 1133

drug interactions, 1113

efficacy of, 1113

mechanism of action, 1112–1113

for PCOS, 1012

pharmacokinetics of, 1112

pharmacologic therapy with, 1132–1133

therapy, 1133

Methadone, 90–91, 1187t, 1906t (see also Opioids)

consensus recommendations for, 1203t

dosage of, 1201–1203, 1202t

for opioid dependence in pregnancy, 1880

for opioid withdrawalsyndrome, 1878, 1879

toxicity

monitoring, 1203

signs and symptoms, 1203

Methamphetamine, 434

for ADHD, 1868t

CNS stimulants, 1884

Methicillin, 692, 1548

for skin and soft tissue infections, 1548

Methicillin-resistant Staphylococcus aureus (MRSA), 1379

Methimazole (Tapazole), 1042, 1059t, 1062, 1064–1065

for thyroid storm, 1067

Methocarbamol, 1186t

for nocturnal leg cramps, 173

Methotrexate (MTX), 469t, 470t, 524, 628, 708, 712t, 713t, 881, 882, 884, 899, 901, 903, 904, 925,

928, 1978t, 1979, 1985–1986, 1991t, 1992, 1995–1996t, 1996, 2022

adverse effects of, 892–893

for ALL, 2017t

cytotoxic effects of, 2009–2010

dosage, 892, 2017–2018

and folate or folinic acid, 893

for inflammatory bowel disease, 521t, 754

interactions, 893

intrathecal, problems of, 2016

and liver biopsy, 893

neurotoxicity of, 1985t

and NSAIDs, 892–893

for ophthalmopathy, 1067

for osteosarcoma, 2008–2009

for psoriasis, 836t, 840

and pulmonary disorders, 893

for T-cell lymphomas, 2020t

teratogenic effects, 973t

Methyldopa, 157t, 984, 985t, 1261t, 2261t

for hypertension in pregnancy, 159

in patients with CKD, 617

for pregestational diabetes, 979

Methylergonovine maleate, 997, 997t

M

e

t

h

yl

p

h

e

n

i

d

a

t

e

,

1

7

7

8

fo

r

A

D

H

D

,

1

8

6

7

t

M

e

t

h

yl

p

r

e

d

n

i

s

o

l

o

n

e

,

6

9

6

,

7

2

1

,

7

2

5

,

7

2

8

,

7

3

8

,

9

2

5

,

9

2

8

inj

e

c

t

io

n

s

,

6

2

6

fo

r

N

V

P

,

9

7

6

t

M

e

t

h

yl

s

a

l

i

c

yl

a

t

e

,

1

1

8

7

t

M

e

t

h

yl

x

a

n

t

h

i

n

e

s

,

fo

r

a

p

n

e

a

,

2

1

8

9

M

e

t

i

p

r

a

n

o

l

o

l

(

O

p

t

i

p

r

a

n

o

l

o

l

)

,

1

1

5

1

M

e

t

o

c

l

o

p

r

a

m

i

d

e

(

R

e

g

l

a

n

)

,

4

1

,

4

7

2

t

,

1

2

6

1

t

,

2

1

6

3

,

2

1

6

3

t

fo

r

dia

b

e

t

e

s

,

1

1

4

5

fo

r

N

V

P

,

9

7

5

,

9

7

6

t

fo

r

P

O

N

V

,

4

7

8

t

p

r

o

kin

e

t

ic

a

g

e

nt

s

,

5

0

8

M

e

t

o

l

az

o

n

e

,

2

7

0

M

e

t

o

p

r

o

l

o

l

,

2

2

0

,

1

0

6

2

,

1

2

7

2

,

2

2

6

1

t

in

a

c

ut

e

s

e

tt

in

g

,

2

5

3

in

H

F

r

E

F

,

2

8

7

–

2

8

8

fo

r

M

I

,

2

5

3

M

e

t

o

p

r

o

l

o

l

s

u

c

c

i

n

a

t

e

,

2

5

8

in

hyp

e

r

t

e

n

s

io

n

,

1

5

9

t

M

e

t

o

p

r

o

l

o

l

t

a

rt

r

a

t

e

,

fo

r

h

yp

e

rt

e

n

s

i

o

n

,

1

5

9

t

,

2

5

3

M

e

t

r

o

n

i

d

az

o

l

e

,

4

9

3

–

4

9

4

t

,

4

9

6

,

5

3

1

,

9

4

2

t

,

1

3

7

0

,

1

7

0

6

,

2

1

5

2

a

dv

e

r

s

e

e

ffe

c

t

s

o

f,

1

5

2

7

fo

r

a

me

b

ic

id

e

s

,

1

7

0

3

t

fo

r

a

n

a

e

r

o

b

e

s

,

1

3

2

8

t

fo

r

b

a

c

t

e

r

ia

l

v

a

g

in

o

s

is

,

1

5

2

2

b

r

a

in

a

b

s

c

e

s

s

a

n

d

,

1

3

8

2

fo

r

B

V

,

9

9

5

fo

r

C

D

I

,

1

4

6

5

fo

r

c

h

o

r

io

a

mnio

nit

is

,

9

9

6

do

s

in

g

o

f,

1

3

3

7

t

fo

r

g

a

s

tr

o

int

e

s

t

in

a

l

in

fe

c

t

io

n

s

,

5

2

4

fo

r

g

ia

r

dia

s

is

,

1

7

0

4

t

,

1

7

0

7

fo

r

P

I

D

,

1

5

1

2

–

1

5

1

3

t

fo

r

s

e

p

s

is

,

2

1

8

6

t

fo

r

s

kin

a

n

d

s

o

ft

t

is

s

u

e

in

fe

c

t

io

n

s

,

1

5

5

0

fo

r

tr

ic

h

o

mo

nia

s

is

,

1

5

2

6–

1

5

2

7

,

1

7

0

5

t

M

e

x

i

l

e

t

i

n

e

,

1

9

0

6

t

M

e

x

o

ryl

S

X,

8

5

2

p. 2

3

0

7

p. 2

3

0

8

M

e

x

o

ryl

XL

,

8

5

2

M

i

b

e

fr

a

d

i

l

,

1

2

8

M

i

c

a

fu

n

g

i

n

,

1

6

2

4

t

,

1

6

2

5

a

dv

e

r

s

e

e

ffe

c

t

s

o

f,

1

3

3

4

t

M

i

c

o

n

az

o

l

e

,

1

5

2

5

t

,

1

6

2

4

t

M

i

c

r

o

n

i

z

e

d

p

r

o

g

e

s

t

e

r

o

n

e

(

P

r

o

m

e

t

ri

u

m

)

,

1

0

3

3

t

M

i

c

r

o

s

o

m

a

l

e

p

o

x

i

d

e

h

y

d

r

o

l

a

s

e

,

9

7

2

M

i

d

az

o

l

a

m

,

fo

r

p

e

d

i

a

t

ri

c

i

n

t

u

b

a

t

i

o

n

,

2

1

9

9

t

M

i

d

o

d

ri

n

e

,

5

4

4

a

dminis

tr

a

t

io

n

,

5

5

5

in

tr

e

a

tme

nt

o

f

I

D

H

,

6

5

7

Mifepristone, 914t

Miglitol, 1125, 1126

Milk of magnesia, 87

Milnacipran, 1194t

Milrinone, 271, 298–299, 2207t

for postoperative cardiac failure, 363t, 364–365

Minocycline, 828, 830, 882, 883, 942t, 1265, 1325t

Minoxidil (Loniten), 157t, 160, 336t

for BP, 339

for hypertensive urgency, 339–340

in patients with CKD, 617

Mipomersen

adverse effects, 129

clinical pearls, 129

drug interactions, 129

efficacy, 128

mechanism of action, 128

pharmacokinetics/pharmacodynamics, 128

place in therapy, 129

Mirabegron, 2252

Miralax, 534

Mirapex (see Pramipexole)

Mirena (see Levonorgestrel-releasing IUD)

Mirtazapine, 1245, 1739, 1827

for depressive disorders, 1819t, 1821t

for diabetes, 2226t

for sleep, 1861

Misoprostol, 483t, 989

enhance mucosal defense mechanisms, 486

and lactation, 1003t

for postpartum hemorrhage, 997, 997t

teratogenic effects, 973t

Mitomycin, 469t, 1978–1979t, 1987, 1991t, 1995t

Mitomycin-C, 1981t

Mitotane, 470t

Mitoxantrone, 469t, 1222, 1979t, 1988

adverse effects of, 1230–1231

monitoring required for, 1231t

for prostate cancer, 2095

MMF (see Mycophenolate mofetil (MMF))

MMR vaccine (see Measles, mumps, rubella (MMR) vaccine)

Modafinil, 942t, 1224, 1777–1779

for ADHD, 1871

Moexipril, in hypertension, 153t

Molindone, for schizophrenia, 1785, 1788

Mometasone/formoterol (Dulera), 396, 816

Mometasone furoate (Nasonex), 441t

for allergic rhinitis, 442

Monoamine oxidase-b inhibitors, 1261t

adverse effects, 1257

dosage of, 1257

for Parkinson’s disease, 1253, 1256–1257, 1264

Monoamine oxidase inhibitors (MAOIs), 1748

for anxiety disorders, 1748

for panic disorder, 1748

and sleep, 1774

Monobactams

adverse effects of, 1332t

for UTI, 1497t

Monocid (see Cefonicid)

Monoclonal antibodies, 1981, 1984

alemtuzumab, 723

basiliximab, 723

Montelukast (Singulair), 440t

MOPP, 2041

Moricizine, 323

Morphine, 677, 677t, 942t, 1178, 1187t, 2131t, 2198 (see also Opioids)

for ACS, 241t

dosage of, 1199t, 1202, 1202t

for end-of-life care, 88–89

for opioid dependence, 1881

for pediatric intubation, 2199t

Morphine sulfate, 248

Moxifloxacin (Avelox), 1326t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CNS infections, 1373t

dosing of, 1337t

for skin and soft tissue infections, 1549, 1552

for tuberculosis, 1430t

MPA (see Mycophenolic acid (MPA))

MRSA (see Methicillin-resistant Staphylococcus aureus (MRSA))

mTOR (see Mammalian target of rapamycin (mTOR))

MTX (see Methotrexate (MTX))

Mucous membrane spray (Zolpimist), 1767t

Multiple endocrine neoplasia type 1 (MEN 1), 501

Multitargeted tyrosine kinase inhibitors, 1989–1990

Multivitamins, 88

alcohol withdrawal, 1896

Mupirocin, 819

MVC (see Maraviroc (MVC))

Mycifradin (see Neomycin)

Mycophenolate mofetil (MMF), 626, 709, 712t, 713t, 928, 942t

for FSGS patients, 629

in liver transplantation, 738–739

and mycophenolate sodium, 721

therapy for Wegener granulomatosis, 628

Mycophenolic acid (MPA), 721

N

Nabilone (Cesamet), 472t, 1204

Nabumetone, 888t

NAC (see N-acetylcysteine (NAC))

N-acetyl-b-d-glucosaminidase, 461

N-acetylcysteine (NAC)

for acetaminophen toxicity, 80–82

antioxidant, 643

duration of therapy of, 81

efficacy of, 81

intravenous, 80

mo

nit

o

r

in

g

e

ffic

a

c

y

o

f,

8

1

o

r

a

l,

8

0–

8

1

in

p

r

e

gn

a

n

c

y

,

8

0

r

o

ut

e

o

f

a

dminis

tr

a

t

io

n

o

f,

8

0

t

o

x

ic

ity

fr

o

m

,

8

1

–

8

2

N

-

a

c

e

t

yl

g

l

u

c

o

s

a

m

i

n

e

,

1

9

9

0

N

-

a

c

e

t

yl

-

p

-

b

e

n

z

o

q

u

i

n

o

n

e

i

m

i

n

e

(

N

A

P

Q

I

)

,

7

9

N

a

d

o

l

o

l

,

1

2

7

1

t

N

a

d

r

o

p

a

ri

n

,

1

3

1

2

N

a

fa

r

e

l

i

n

(

S

y

n

a

r

e

l

)

,

1

0

2

0

t

,

1

0

2

1

N

a

fc

i

l

l

i

n

(

O

x

a

c

i